Bristol-Myers Squibb and PureTech's Vedanta Biosciences Announce New Immuno-Oncology Collaboration to Evaluate OPDIVO (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers

Media coverage

• Title	Bristol-Myers Squibb and PureTech's Vedanta Biosciences Announce New Immuno-Oncology Collaboration to Evaluate OPDIVO (nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
  Media name/outlet	India Pharma News
  Country/Territory	India
  Date	10/12/18
  Persons	Jeremiah Faith

• Title	Bristol-Myers Squibb and Vedanta Biosciences Announce a New Clinical Collaboration to Evaluate OPDIVO (Nivolumab) and VE800 in Patients with Advanced or Metastatic Cancers
  Media name/outlet	India Pharma News
  Country/Territory	India
  Date	10/12/18
  Persons	Jeremiah Faith